Stealth BioTherapeutics Reports Fiscal Year 2020 Financial Results And Recent Business Highlights

BOSTON, April 6, 2021 /PRNewswire/ — Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the year ended December 31, 2020 and announced recent business highlights.

“As we look forward to data from our fully-enrolled Phase 2 program in dry age-related macular degeneration during the first half of 2022, we are poised to progress our planned clinical expansion into rare metabolic cardiomyopathies and neurological diseases, with multiple trial initiations expected this year,” said Reenie McCarthy, Chief Executive Officer

Govt Defers Implementation Of Necessary Use Of Transparent Accounting Software Until Future Year

In a reduction to companies across the spectrum, the authorities has extended deadline for required adoption of accounting software program possessing audit path of every and just about every transaction and having attribute to keep logs of edits.

As for each a new notification by the Ministry of Company Affairs (MCA), implementation of necessary use of accounting software program having Audit Trail as offered under proviso to Rule 3 of the Firms (Accounts) Regulations, 2014 has been deferred till 31 March 2022.

The modifications have been previously proposed to be implemented from 1 April 2021. But after acquiring several representations

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

– Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a total of $358 million in recent fundraising –

– Advanced first-in-class Boltbody ISAC into the clinic in 2020 and continued to expand pipeline of pioneering immuno-oncology assets –

– Reported positive preliminary data from first 20 patients treated with the HER2-targeting Boltbody ISAC BDC-1001 in ongoing Phase 1/2 clinical trial in early 2021; monotherapy dose expansion and anti-PD-1 antibody combination parts of study expected to start in 2H, 2021 –

REDWOOD CITY, Calif., March 31, 2021 (GLOBE NEWSWIRE) —

BiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

NESS ZIONA, Israel–(BUSINESS WIRE)–Mar 31, 2021–

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020.

“2020 was a tremendous year of growth for BiomX, as we expanded our pipeline with programs in cystic fibrosis and atopic dermatitis, both designed to address unmet medical needs,” said Jonathan Solomon, Chief Executive Officer of BiomX. “Fueled by the rapid development capabilities of our novel BOLT platform, we

Frequency Therapeutics Supplies Enterprise Updates and Reports Fourth Quarter and Full Year 2020 Fiscal Results

WOBURN, Mass.–(Enterprise WIRE)–Mar 29, 2021–

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a medical-stage biotechnology organization concentrated on harnessing the body’s innate biology to repair service or reverse injury brought on by a wide variety of degenerative diseases, right now announced company updates and economic effects for the fourth quarter and calendar year ended December 31, 2020.

“We a short while ago attained worthwhile info from two clinical experiments in people with sensorineural listening to decline that have delivered us with important learnings that now are informing our upcoming growth strategies for Fx-322, specifically around demo design and style and using a

I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates

  • 18 significant clinical milestones achieved since the Company’s IPO in January 2020, with multiple important data readouts for lemzoparlimab (TJC4), uliledlimab (TJD5) and other clinical assets expected in 2021

  • New drug application (NDA) submission for felzartamab (TJ202) CD38 antibody for treatment of relapsed or refractory multiple myeloma on track for 2021

  • Achieved corporate profitability, delivering full-year net revenues of RMB 1,542.7 million (US $236.4 million), net income per ADS of RMB 8.07 (US $1.24) on a GAAP basis and net income per ADS of RMB 17.09 (US $2.62) on a non-GAAP basis

  • Total cash position of RMB 4.8 billion (US

Evolus Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update

Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau®

Pro Forma Cash Position of $57 Million at December 31, 20201

NEWPORT BEACH, Calif., March 24, 2021 (GLOBE NEWSWIRE) — Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2020.

“Over the past several months, we successfully transformed our business by settling the International Trade Commission case and related litigation, eliminating $127 million of debt and payment

Celyad Oncology Reports Full Year 2020 Financial Results and Recent Business Highlights

  • No safety concerns or evidence of Graft-versus-Host disease reported from first dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM); enrollment in second dose cohort initiated with additional proof-of-concept data anticipated in Q2 2021

  • Enrollment ongoing in expansion segment of Phase 1 alloSHRINK trial evaluating CYAD-101 administered concurrently with FOLFIRI preconditioning chemotherapy for the treatment of advanced metastatic colorectal cancer (mCRC); preliminary data from expansion cohort expected in Q2 2021

  • On track to initiate Phase 1b KEYNOTE-B79 trial evaluating CYAD-101 with KEYTRUDA® in patients with microsatellite stable

Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

– Advanced ALG-010133 and ALG-000184 into the clinic – both expected to generate safety and antiviral activity data in Chronic Hepatitis B (CHB) patients in 2021
– Listed on NASDAQ Global Select Market under the symbol ALGS and raised $167.2 million in gross proceeds from the Initial Public Offering (IPO), inclusive of the underwriters’ exercise of their overallotment option
– Cash, Cash Equivalents and investments of $243.5 million as of December 31, 2020

SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address

Newtek Business Services Corp. Reports Full Year 2020 Financial Results

BOCA RATON, Fla., March 22, 2021 (GLOBE NEWSWIRE) — Newtek Business Services Corp. (“Newtek” or the “Company”) (Nasdaq: NEWT), an internally managed business development company (“BDC”), announced today its financial and operating results for the twelve months ended December 31, 2020.

Full Year 2020 Financial Highlights

  • Net investment income of $32.0 million, or $1.51 per share, for the twelve months ended December 31, 2020; an increase of 620.7{f13b67734a7459ff15bce07f17c500e58f5449212eae0f7769c5b6fbcf4cc0c4}, on a per share basis, compared to net investment loss of $(5.6) million, or $(0.29) per share, for the twelve months ended December 31, 2019.
  • Adjusted net investment income (“ANII”)1 of

Newswire’s Earned Media Gain Guided Tour Marketplace Builder Helps Accounting Corporations Industry Their Companies During Tax Year

NEW YORK – March 22, 2021 – ( )

April 15 is more than just a working day on the calendar. For Us citizens, April 15 is recognised as “Tax Day”, which is the deadline for distributing money tax returns to the federal authorities. 

This 12 months by itself, the Inside Earnings Services (IRS) expects to system close to 150 million tax returns. 

As Tax Day draws near, most tax gurus are centered entirely on completing tax returns for their customers. This generates a window of prospect that Newswire has identified for its accounting organization consumers to capitalize on

Newest ezAccounting Organization and Payroll Software package Has Been Up-to-date To Contain the 2021 Calendar year 941 Kind


3 Monster Expansion Shares With Possible for Further more Gains

At the end of the working day, buyers want to see returns. To carry out this purpose, seasoned Wall Street observers usually flip to one strategy time and time once again: expansion investing. A reliable growth enjoy is a title that appears poised to not only mature at an higher than-ordinary level but also reward traders handsomely above the very long run. Rolling up their sleeves, buyers are pounding the Wall Road pavement in lookup of the tickers with extraordinary extensive-time period progress potential clients. Having said that, obtaining

Accounting specialists expose 5 indicators your textbooks usually are not prepared for tax year

Compact business house owners have a great deal to believe about at the begin of the yr. For most, tax time is in close proximity to the leading of the record. The crucial to a pain-free tax season lies in preparing. At the get started of the year, acquire a tricky seem at your books to make certain every thing is tracked and structured. Clean, correct textbooks make it easier for you and your accountant to file your organization taxes and increase your deductions.

But how can you tell if your textbooks are in tiptop form? We questioned 5 accounting

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly

Reported interim data from Phase 1/2a study of PBCAR0191; updated interim data expected
by mid-year 2021

Interim data releases expected from PBCAR269A and PBCAR20A in 2021

Received FDA acceptance of IND application for PBCAR19B, a next-generation, stealth cell,
anti-CD19 allogeneic CAR T candidate for non-Hodgkin lymphoma; Phase 1 study expected to be initiated by mid-year 2021

DURHAM, N.C., March 18, 2021 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS® genome editing platform, today

Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update

  • Legend received approximately $659.8 million in gross proceeds through share capital increases during 2020, including a successful Nasdaq IPO with aggregate gross proceeds of $487.3 million.

  • U.S. FDA clearance for IND application for a Phase 1 clinical trial to evaluate LB1901 in relapsed or refractory T-cell lymphoma (RR TCL).

  • Rolling submission of BLA to the FDA initiated for cilta-cel for the treatment of relapsed or refractory multiple myeloma (RRMM).

  • Cash and cash equivalents and time deposits of $505.7 million as of December 31, 2020.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery

Ocugen Provides Business Update and Full Year 2020 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET

  • COVID-19 vaccine candidate, COVAXIN™, demonstrates efficacy of 81{f13b67734a7459ff15bce07f17c500e58f5449212eae0f7769c5b6fbcf4cc0c4} in Phase 3 interim results

  • Emergency Use Authorization pathway with U.S. regulatory authorities in development for COVAXIN™

  • European Commission grants orphan medicinal product designation for OCU400 for retinitis pigmentosa and leber congenital amaurosis and Ocugen is on track to submit an Investigational New Drug application for OCU400 in 2021

  • On track to initiate four Phase 1/2 clinical trials encompassing Ocugen’s ophthalmology pipeline in 2021 and 2022

MALVERN, Pa., March 18, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN), a biopharmaceutical company focused

PLAYSTUDIOS, Inc. Announces Preliminary Fourth Quarter and Full Year 2020 Results Along With Recent Business Highlights

Fourth Quarter Revenue of $64.0 million and Full Year 2020 Revenue of $269.9 million, representing year-over-year growth of 12.9{f13b67734a7459ff15bce07f17c500e58f5449212eae0f7769c5b6fbcf4cc0c4} and 12.7{f13b67734a7459ff15bce07f17c500e58f5449212eae0f7769c5b6fbcf4cc0c4} respectively

Company entered the Casual Bingo market in 1Q2021 with its myVEGAS Bingo product, bringing real-world rewards and loyalty benefits to this robust category

PLAYSTUDIOS, Inc. (“PLAYSTUDIOS” or the “Company”), an award-winning developer of free-to-play casual games for mobile and social platforms that offer real-world rewards to loyal players, today announced preliminary financial results for the fourth quarter and full year ended December 31, 2020. The preliminary results are subject to completion of the Company’s year-end financial

Most current ezAccounting Business enterprise and Payroll Program Has Been Up-to-date To Involve the 2021 Year 941 Sort


Worldwide disposable syringe industry was valued USD16.68 billion in price terms in 2020 and is forecast to develop at CAGR of 8.78{f13b67734a7459ff15bce07f17c500e58f5449212eae0f7769c5b6fbcf4cc0c4} in worth conditions to attain USD27.45 billion by 2026

World wide Disposable Syringes Industry, By Type (Regular Syringes, Pre-filled Syringes, Security Syringes), By Application (Normal Medical procedures, Diagnostic, Therapeutic, Respiratory, Orthopedics, Cardiovascular, Dental, Other folks), By End User (Hospitals, Diagnostic Laboratories, Blood Banking companies, Pharmaceutical Industry, Vaccination, Veterinary Uses, Many others), By Product (Glass, Polymer), By Location, Forecast & Possibilities, 2026New York, March 17, 2021 (Globe NEWSWIRE) — announces the launch of the report “World-wide Disposable

Salesforce Husband or wife, Accounting Seed, Celebrates A single Calendar year of Accounting Seed College

Push launch content material from PR Newswire. The AP news staff members was not associated in its development.

COLUMBIA, Md., March 16, 2021 /PRNewswire/ — Accounting Seed celebrates a 12 months of on the net education via the company’s discovering management method, Accounting Seed University (ASU). Released on March 16, 2020, ASU is driven by the quantity one on-line finding out platform, TalentLMS, and provides about 150 new users each and every quarter. With ASU and the company’s Awareness Foundation (KB), customers and associates have entry to tutorial teaching to aid in fast platform

Salesforce Companion, Accounting Seed, Celebrates One Year of Accounting Seed College

Salesforce Associate, Accounting Seed, Celebrates A person Year of Accounting Seed College

Salesforce Husband or wife, Accounting Seed, Celebrates A person Calendar year of Accounting Seed College

PR Newswire

COLUMBIA, Md., March 16, 2021

COLUMBIA, Md., March 16, 2021 /PRNewswire/ — Accounting Seed celebrates a calendar year of on line instruction by way of the company’s learning management program, Accounting Seed College (ASU). Released on March 16, 2020, ASU is driven by the range one online learning platform, TalentLMS, and provides in excess of 150 new consumers each quarter. With ASU and the firm’s Expertise Foundation (KB), shoppers and